Identification of Compounds With Potential Dual Inhibitory Activity Against Drug Efflux Pumps in Resistant Cancer...

Area of Science:

• Pharmacology
• Molecular Biology
• Drug Discovery

Background:

• Multidrug resistance (MDR) in bacteria and cancer cells is often mediated by drug efflux pumps.
• Developing efflux pump inhibitors is a key strategy to overcome MDR.
• Identifying compounds with dual activity against both bacterial and cancer MDR is highly desirable.

Purpose of the Study:

• To systematically review compounds that reverse both antibacterial and cancer MDR.
• To identify structural and biological parameters influencing efflux pump interactions.
• To provide a foundation for rational drug design of dual efflux pump inhibitors.

Main Methods:

• Systematic review following PRISMA-P guidelines.
• Searched PubMed and Scopus databases (Jan 2012 - Sep 2024).
• Included in vitro studies assessing changes in sensitivity to antimicrobials and chemotherapeutics upon treatment with efflux pump inhibitors.

Main Results:

• Anticipate outlining potential dual-acting chemosensitizers.
• Results will highlight compounds capable of reversing both antimicrobial and cancer MDR.
• Data will be synthesized narratively and presented in tabular and graphical formats.

Conclusions:

• Efflux pump inhibition is a viable strategy for combating MDR in both bacteria and cancer.
• This review will underscore the overlap in resistance mechanisms.
• Structured data will facilitate the rational design of novel dual efflux pump inhibitors.